Hologic, Inc. $HOLX Shares Purchased by Vident Advisory LLC

Key Points

• Vident Advisory LLC significantly increased its stake in Hologic, Inc., buying 15,063 shares and lifting its ownership by 256.6% to a total of 20,933 shares, valued at approximately $1.29 million.
• Other institutional investors also raised their investments in Hologic, with notable increases from Victory Capital Management Inc. (up 34.4%) and Nuance Investments LLC (up 623.7%), indicating a strong interest in the company's stock.
• Hologic reported a quarterly earnings per share of $1.08, exceeding estimates, with revenue reaching $1.02 billion, and set its Q4 2025 guidance between $1.090-$1.120 EPS.

Vident Advisory LLC raised its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 256.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,933 shares of the medical equipment provider's stock after acquiring an additional 15,063 shares during the quarter. Vident Advisory LLC's holdings in Hologic were worth $1,293,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Zions Bancorporation National Association UT acquired a new stake in Hologic in the first quarter valued at $34,000. Allworth Financial LP grew its stake in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after acquiring an additional 216 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Hologic in the 1st quarter valued at about $42,000. Larson Financial Group LLC increased its holdings in Hologic by 6,016.7% during the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 722 shares in the last quarter. Finally, Raiffeisen Bank International AG acquired a new position in Hologic during the fourth quarter worth about $49,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and boosted their price target for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Evercore ISI lifted their price objective on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Morgan Stanley upped their price target on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Mizuho set a $75.00 price target on Hologic in a report on Thursday, July 31st. Finally, Stephens decreased their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Stock Up 0.6%

Shares of Hologic stock traded up $0.37 during trading on Friday, reaching $66.76. The company had a trading volume of 1,270,243 shares, compared to its average volume of 1,601,091. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The firm's fifty day moving average is $66.34 and its 200-day moving average is $62.61. The company has a market cap of $14.85 billion, a price-to-earnings ratio of 27.70, a price-to-earnings-growth ratio of 2.41 and a beta of 0.57.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the company earned $1.06 earnings per share. Hologic's quarterly revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.